Compare ALG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | MESO |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1996 | N/A |
| Metric | ALG | MESO |
|---|---|---|
| Price | $161.05 | $15.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $225.00 | N/A |
| AVG Volume (30 Days) | ★ 151.2K | 123.6K |
| Earning Date | 05-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $1,603,715,000.00 | N/A |
| Revenue This Year | $5.26 | $629.74 |
| Revenue Next Year | $3.97 | $30.65 |
| P/E Ratio | $66.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $145.76 | $10.17 |
| 52 Week High | $233.29 | $21.50 |
| Indicator | ALG | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 59.17 |
| Support Level | $158.84 | $13.71 |
| Resistance Level | $181.19 | $16.11 |
| Average True Range (ATR) | 4.49 | 0.49 |
| MACD | 1.68 | 0.09 |
| Stochastic Oscillator | 86.48 | 84.89 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.